The Experts below are selected from a list of 45 Experts worldwide ranked by ideXlab platform
M S Golub - One of the best experts on this subject based on the ideXlab platform.
-
Identifying individual differences of fluoxetine response in juvenile rhesus monkeys by metabolite profiling
Translational Psychiatry, 2014Co-Authors: C E Hogrefe, D Grapov, M Palazoglu, O Fiehn, C W Turck, M S GolubAbstract:Fluoxetine is the only Psychopharmacological Agent approved for depression by the US Food and Drug Administration for children and is commonly used therapeutically in a variety of neurodevelopmental disorders. Therapeutic response shows high individual variability, and severe side effects have been observed. In the current study we set out to identify biomarkers of response to fluoxetine as well as biomarkers that correlate with impulsivity, a measure of reward delay behavior and potential side effect of the drug, in juvenile male rhesus monkeys. The study group was also genotyped for polymorphisms of monoamine oxidase A (MAOA), a gene that has been associated with psychiatric disorders. We used peripheral metabolite profiling of blood and cerebrospinal fluid (CSF) from animals treated daily with fluoxetine or vehicle for one year. Fluoxetine response metabolite profiles and metabolite/reward delay behavior associations were evaluated using multivariate analysis. Our analyses identified a set of plasma and CSF metabolites that distinguish fluoxetine- from vehicle-treated animals and metabolites that correlate with impulsivity. Some metabolites displayed an interaction between fluoxetine and MAOA genotype. The identified metabolite biomarkers belong to pathways that have important functions in central nervous system physiology. Biomarkers of response to fluoxetine in the normally functioning brain of juvenile nonhuman primates may aid in finding predictors of response to treatment in young psychiatric populations and in progress toward the realization of a precision medicine approach in the area of neurodevelopmental disorders.
Casey E. Hogrefe - One of the best experts on this subject based on the ideXlab platform.
-
Fluoxetine: juvenile pharmacokinetics in a nonhuman primate model
Psychopharmacology, 2014Co-Authors: Mari S. Golub, Casey E. HogrefeAbstract:Rationale The selective serotonin reuptake inhibitor (SSRI) fluoxetine is the only Psychopharmacological Agent approved for use in children. While short-term studies of side effects have been performed, long-term consequences for brain development are not known. Such studies can be performed in appropriate animal models if doses modeling therapeutic use in children are known.
O A Andreassen - One of the best experts on this subject based on the ideXlab platform.
-
The promise and pitfalls of intranasally administering Psychopharmacological Agents for the treatment of psychiatric disorders
Molecular Psychiatry, 2016Co-Authors: D S Quintana, A J Guastella, L T Westlye, O A AndreassenAbstract:Accumulating research demonstrates the potential of intranasal delivery of Psychopharmacological Agents to treat a range of psychiatric disorders and symptoms. It is believed that intranasal administration offers both direct and indirect pathways to deliver Psychopharmacological Agents to the central nervous system. This administration route provides a unique opportunity to repurpose both old drugs for new uses and improve currently approved drugs that are indicated for other administration routes. Despite this promise, however, the physiology of intranasal delivery and related assumptions behind the bypassing of the blood brain barrier is seldom considered in detail in clinical trials and translational research. In this review, we describe the current state of the art in intranasal Psychopharmacological Agent delivery research and current challenges using this administration route, and discuss important aspects of nose-to-brain delivery that may improve the efficacy of these new therapies in future research. We also highlight current gaps in the literature and suggest how research can directly examine the assumptions of nose-to-brain delivery of Psychopharmacological Agents in humans.
C E Hogrefe - One of the best experts on this subject based on the ideXlab platform.
-
Identifying individual differences of fluoxetine response in juvenile rhesus monkeys by metabolite profiling
Translational Psychiatry, 2014Co-Authors: C E Hogrefe, D Grapov, M Palazoglu, O Fiehn, C W Turck, M S GolubAbstract:Fluoxetine is the only Psychopharmacological Agent approved for depression by the US Food and Drug Administration for children and is commonly used therapeutically in a variety of neurodevelopmental disorders. Therapeutic response shows high individual variability, and severe side effects have been observed. In the current study we set out to identify biomarkers of response to fluoxetine as well as biomarkers that correlate with impulsivity, a measure of reward delay behavior and potential side effect of the drug, in juvenile male rhesus monkeys. The study group was also genotyped for polymorphisms of monoamine oxidase A (MAOA), a gene that has been associated with psychiatric disorders. We used peripheral metabolite profiling of blood and cerebrospinal fluid (CSF) from animals treated daily with fluoxetine or vehicle for one year. Fluoxetine response metabolite profiles and metabolite/reward delay behavior associations were evaluated using multivariate analysis. Our analyses identified a set of plasma and CSF metabolites that distinguish fluoxetine- from vehicle-treated animals and metabolites that correlate with impulsivity. Some metabolites displayed an interaction between fluoxetine and MAOA genotype. The identified metabolite biomarkers belong to pathways that have important functions in central nervous system physiology. Biomarkers of response to fluoxetine in the normally functioning brain of juvenile nonhuman primates may aid in finding predictors of response to treatment in young psychiatric populations and in progress toward the realization of a precision medicine approach in the area of neurodevelopmental disorders.
Mari S. Golub - One of the best experts on this subject based on the ideXlab platform.
-
Fluoxetine: juvenile pharmacokinetics in a nonhuman primate model
Psychopharmacology, 2014Co-Authors: Mari S. Golub, Casey E. HogrefeAbstract:Rationale The selective serotonin reuptake inhibitor (SSRI) fluoxetine is the only Psychopharmacological Agent approved for use in children. While short-term studies of side effects have been performed, long-term consequences for brain development are not known. Such studies can be performed in appropriate animal models if doses modeling therapeutic use in children are known.